RxDoctor Payments Data

Jeffery Brown, MD

Family Medicine · Lafayette, LANPI 1720008766

Payments from drug & device makers

$1,426in general payments, 2019–2025

Across 87 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$475
  • Novo Nordisk$421
  • AbbVie$299
  • Medtronic$119
  • Sanofi Pasteur Inc.$23
  • Johnson & Johnson$20
  • plus $70 from 5 others

What the payments were for

  • Food & beverage$1,41399%
  • Entertainment$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,426 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$140,832
Medicare patients
366
Services billed
4,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$93,132
JardianceEmpagliflozin35$22,758
XareltoRivaroxaban28$22,128
EliquisApixaban15$10,324
Breo ElliptaFluticasone/Vilanterol19$9,882
LinzessLinaclotide12$8,956
Tresiba Flextouch U-200Insulin Degludec13$7,953
FarxigaDapagliflozin Propanediol12$7,875
Incruse ElliptaUmeclidinium Bromide15$6,926
Atorvastatin Calcium309$2,838
Rosuvastatin Calcium177$2,229
Escitalopram Oxalate89$1,524
Ezetimibe61$1,441
Pantoprazole Sodium83$1,381
Amlodipine Besylate180$1,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$421$93,13296 claims
Johnson & JohnsonXarelto$20$22,12828 claims
PfizerEliquis$475$10,32415 claims
AbbVieLinzess$299$8,95612 claims
AstraZenecaFarxiga$15$7,87512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →